1. Home
  2. RXT vs MGNX Comparison

RXT vs MGNX Comparison

Compare RXT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rackspace Technology Inc.

RXT

Rackspace Technology Inc.

N/A

Current Price

$1.92

Market Cap

120.0M

Sector

Technology

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

N/A

Current Price

$3.34

Market Cap

115.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RXT
MGNX
Founded
1998
2000
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.0M
115.8M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
RXT
MGNX
Price
$1.92
$3.34
Analyst Decision
Hold
Hold
Analyst Count
6
5
Target Price
$1.71
$3.40
AVG Volume (30 Days)
47.9M
1.2M
Earning Date
06-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
75.13
N/A
EPS
N/A
N/A
Revenue
$2,685,700,000.00
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$0.99
52 Week High
$2.74
$3.50

Technical Indicators

Market Signals
Indicator
RXT
MGNX
Relative Strength Index (RSI) 58.48 87.97
Support Level $1.13 $1.42
Resistance Level $2.74 N/A
Average True Range (ATR) 0.43 0.18
MACD 0.01 0.15
Stochastic Oscillator 43.40 91.34

Price Performance

Historical Comparison
RXT
MGNX

About RXT Rackspace Technology Inc.

Rackspace Technology Inc is an end-to-end, hybrid, multi cloud technology services company. It designs, builds and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services; Data; Colocation; Cloud; Managed Hosting; Professional Services; and Security & Compliance. It operates in segments namely, Private Cloud, and Public Cloud. It generates revenue through the sale of consumption-based contracts for its service offerings and from the sale of professional services related to designing and building custom solutions.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: